

Specialty Guideline Management

Zepzelca

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Zepzelca	lurbinectedin

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹

Zepzelca is indicated:

- In combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide
- for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Compendial Uses²

- Relapsed small cell lung cancer
- Primary progressive small cell lung cancer

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Small Cell Lung Cancer^{1,2}

Authorization of 12 months may be granted for treatment of small cell lung cancer in any of the following regimens:

- As a single agent for subsequent treatment of any of the following:
 - Relapse following complete or partial response or stable disease with initial treatment
 - Primary progressive disease
 - Metastatic disease following disease progression on or after platinum-based chemotherapy
- In combination with atezolizumab or atezolizumab and hyaluronidase-tqjs as maintenance treatment for extensive stage disease if no progression after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Zepzelca [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; October 2025.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed October 22, 2025.